Sylvestre Le Moulec
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sylvestre Le Moulec has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Adrien Dixmier
Service de Pneumologie, Centre Hospitalier Régional, Orléans, France
1 shared publication - Aldo Renault
Service de Pneumologie, Centre Hospitalier Pau, 64000 Pau, France
1 shared publication - Alexandra Langlais
IFCT Intergroupe Francophone de Cancérologie Thoracique, 10 Rue de la Grange Batelière, 75009 Paris, France
1 shared publication - Alexis Benjamin Cortot
CNRS, Inserm, Institut Pasteur de Lille, UMR9020‐UMR1277‐Canther‐Cancer Heterogeneity, Plasticity and Resistance to Therapies, Univ. Lille CHU Lille Lille France
1 shared publication - Amandine Crombé
SARCOTARGET Team, Inserm, UMR1312, BRIC, Bordeaux Institute of Oncology, University of Bordeaux, 33000 Bordeaux, France
1 shared publication - Antoine Italiano
Gustave Roussy Cancer Institute, Paris-Saclay University, DITEP, Villejuif, France
1 shared publication
Latest Publications
- Open Access
- 25 June 2018
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 11 (1) , 86
Targeting ERBB2 mutations in solid tumors: biological and clinical implications
Preclinical data have shown that ERBB2 activating mutations are responsive to HER2 tyrosine kinase inhibitors. The aim of this study is to characterize the landscape of ERBB2 mutations in solid tumors and the potential efficacy of ERBB2 targeting. We analyzed the next-generation sequencing results from 17,878 patients with solid tumors and reported the outcome of 4 patients with advanced ERBB2-mutated tumors treated with a combination of trastuzumab and lapatinib. ERBB2 mutations occurred in 510 patients (2.85%). The tumor types with the highest incidence of ERBB2 mutations were the following: bladder (16.6%), small bowel (8.6%), ampullar (6.5%), skin non-melanoma (6.1%), and cervical cancer (5.5%). 49.4% (n = 282) were known as activating mutations. ERBB2 mutation was not mutually exclusive of ERBB2 amplification which occurred in up to 10% of cases. PI3KCA activating mutations were associated with ERBB2 mutations in 12.4% of cases mainly in breast and lung cancer. Four patients (endometrial, colorectal, cholangiocarcinoma, and adenosarcoma of the uterus) were treated with a combination of trastuzumab and lapatinib. All of them experienced tumor shrinkage resulting in stable disease in three cases and partial response in one case. One patient developed secondary resistance. Sequencing of the progressing metastasis allowed the identification of the ERBB2 L869R mutation previously associated with resistance to lapatinib in vitro. These results support further clinical investigation aiming to demonstrate that ERBB2-mutational driven therapy can improve patient care irrespective of histology.
- 25 June 2018
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 11 (1) , 86
Open AccessTargeting ERBB2 mutations in solid tumors: biological and clinical implications
Preclinical data have shown that ERBB2 activating mutations are responsive to HER2 tyrosine kinase inhibitors. The aim of this study is to characterize the landscape of ERBB2 mutations in solid tumors and the potential efficacy of ERBB2 targeting. We analyzed the next-generation sequencing results from 17,878 patients with solid tumors and reported the outcome of 4 patients with advanced ERBB2-mutated tumors treated with a combination of trastuzumab and lapatinib. ERBB2 mutations occurred in 510 patients (2.85%). The tumor types with the highest incidence of ERBB2 mutations were the following: bladder (16.6%), small bowel (8.6%), ampullar (6.5%), skin non-melanoma (6.1%), and cervical cancer (5.5%). 49.4% (n = 282) were known as activating mutations. ERBB2 mutation was not mutually exclusive of ERBB2 amplification which occurred in up to 10% of cases. PI3KCA activating mutations were associated with ERBB2 mutations in 12.4% of cases mainly in breast and lung cancer. Four patients (endometrial, colorectal, cholangiocarcinoma, and adenosarcoma of the uterus) were treated with a combination of trastuzumab and lapatinib. All of them experienced tumor shrinkage resulting in stable disease in three cases and partial response in one case. One patient developed secondary resistance. Sequencing of the progressing metastasis allowed the identification of the ERBB2 L869R mutation previously associated with resistance to lapatinib in vitro. These results support further clinical investigation aiming to demonstrate that ERBB2-mutational driven therapy can improve patient care irrespective of histology.
- 23 October 2017
- Published by Elsevier in Annals of Oncology
- Vol. 29 (2) , 514-515
A fatal allo- and immune-mediated thrombocytopenia with a PD-L1 inhibitor
PD1/PD-L1 inhibitors can be prescribed as second-line treatment and have also emerged as a first-line treatment in non-small-cell lung cancer patients (in patients with high PD-L1 expression) [1]. While these inhibitors are generally well-tolerated, adverse uncommon immune-related events can still occur which need to be addressed to prevent negative effects on outcome.
- 23 October 2017
- Published by Elsevier in Annals of Oncology
- Vol. 29 (2) , 514-515
A fatal allo- and immune-mediated thrombocytopenia with a PD-L1 inhibitor
PD1/PD-L1 inhibitors can be prescribed as second-line treatment and have also emerged as a first-line treatment in non-small-cell lung cancer patients (in patients with high PD-L1 expression) [1]. While these inhibitors are generally well-tolerated, adverse uncommon immune-related events can still occur which need to be addressed to prevent negative effects on outcome.